AstraZeneca PLC on Thursday said its antibody Imfinzi, when used with chemotherapy, significantly improved responses in a form of cell lung cancer.
The study researched resectable non-small cell lung cancer. In a phase 3 trial, Imfinzi, also known as durvalumab, ‘demonstrated a statistically significant and meaningful improvement,’ when used in combination with a form of chemotherapy before surgery. The improvement was compared to patients who received almost the same treatment, but without Imfinzi.
Separately, citing a Lancet-published study that was sponsored by AstraZeneca, the Cambridge-based pharmaceutical company said about 10% of all adults suffer from new chronic kidney disease. The disease kills about 6% to 9% of people who have it every year, for example by causing heart failure. The study involved 2.4 million chronic kidney disease patients.
‘CKD is a growing global health burden with increasing contribution to total mortality, and substantial financial costs and impact on healthcare providers,’ AstraZeneca said.
In August 2021, AstraZeneca’s inhibitor Forxiga, also known as dapagliflozin and as Farxiga in the US, received EU approval for the treatment of some patients with chronic kidney disease.
It highlighted that the treatment was only approved for people with and without type-2 diabetes. Forxiga is a sodium–glucose co-transporter 2 inhibitor, which is also approved by the EU for the treatment of type-2 diabetes and heart failure with reduced ejection fraction.
AstraZeneca shares were 1.3% lower at 10,908.00 pence each in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
